LIPO-102 is Lithera’s novel injectable combination of salmeterol xinafoate (SX) and fluticasone propionate (FP) for selective, non-ablative fat reduction.
LIPO-102 is currently under development for the treatment of symptomatic exophthalmos (protrusion of the eye from the orbit) associated with thyroid-related eye disease (the thyroid condition is also known as Graves’ Disease) and the reduction of abdominal adiposity.
Lithera said that once issued, the patent will afford the company market exclusivity for LIPO-102 into 2028.